Greetings From the Editor of *Clinical Thyroidology*

DEAR COLLEAGUES,

In this month's issue, we again review and provide expert commentaries of a "top 10" of the most interesting recent papers in the clinical thyroid literature. Dr. Haixia Guan examines a study reporting the decreasing trend of elevated serum TSH values used to begin thyroid hormone replacement over a 15-year period in a large Danish registry. These data suggest that our threshold for treating hypothyroidism is falling—thus, is there potential overtreatment of hypothyroidism? Dr. Mary Samuels reviews a study that suggests that undertreated hyperthyroidism (both subclinical and overt) correlates with adverse cardiovascular risks that persist if the treatment is inadequate. Dr. David Cooper discusses a Japanese article about patients with Graves' disease that is one of the largest studies of the use of antithyroid medical therapy to date; the study also represents one of the longest follow-up periods in the available literature on this topic. In the areas of pregnancy and pediatrics, Dr. Sun Lee reviews a paper on the effect of thyroid Ab positivity on the thyroid's response to hCG during gestation, while Dr. Catherine Dinanier examines a large cohort study suggesting that morbidity from thyroid surgery among children is correlated with the surgeon's volume of operations.

Regarding thyroid nodules and thyroid cancer, Drs. Martin Biermann and Katrin Brauckhoff review a study proposing the utility of preoperative PET/CT scanning in patients with medullary thyroid carcinoma and basal calcitonin concentrations >1000 pg/ml. Drs. Catherine Zhu, Masha Livhits, and Michael Yeh comment on an interesting paper that suggests that the management of thyroid nodules and thyroid cancer may be more cost-effective in the approaches outlined by the ATA's 2015 guidelines on this topic, in comparison to the society's 2009 guidelines. Dr. Lisa Orloff examines a paper summarizing the patient experience in Japan of the longest-standing and largest thyroid cancer active surveillance program to date. Dr. Brian Kim reviews a study assessing the

responses to I-131 and other treatment in patients with bony metastases in differentiated thyroid cancer. Finally, Dr. Daniel Toft presents an insightful look at an article examining the risk of medullary thyroid cancer in patients with diabetes being treated with GLP-1 agonists—is there a true risk as suggested by the animal data on this topic?

I continue to invite you all to follow us through our social media channels listed below. The journal's reach is steadily growing through these important means of communication, and there is a lot of wonderful chatter from and with colleagues all over the globe on the topics we cover. Check us out at:

Twitter: [@clinicalthyroid](https://twitter.com/clinicalthyroid)

Facebook: <https://www.facebook.com/ThyroidAssociation>

LinkedIn: <https://www.linkedin.com/company/american-thyroid-association>

Youtube: <https://www.youtube.com/user/thyroidorg>

Finally, thank you for your continued interest in and readership of the journal. I hope that you find the topics we cover to be directly relevant and impactful to the care of your patients. Please feel free to send me any questions or comments at clinicalthyroidology@thyroid.org.

Warm regards,

Angela M. Leung, MD, MSc
Editor-in-Chief, *Clinical Thyroidology*